KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Common Equity (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Common Equity for 8 consecutive years, with $765.3 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 33.48% to $765.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $765.3 million through Dec 2025, down 33.48% year-over-year, with the annual reading at $765.3 million for FY2025, 33.48% down from the prior year.
  • Common Equity hit $765.3 million in Q4 2025 for Vir Biotechnology, down from $796.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $2.1 billion in Q3 2022 to a low of $651.0 million in Q1 2021.
  • Historically, Common Equity has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2021.
  • Biggest five-year swings in Common Equity: skyrocketed 207.4% in 2022 and later crashed 35.84% in 2025.
  • Year by year, Common Equity stood at $1.4 billion in 2021, then skyrocketed by 45.12% to $2.1 billion in 2022, then dropped by 23.47% to $1.6 billion in 2023, then fell by 27.66% to $1.2 billion in 2024, then plummeted by 33.48% to $765.3 million in 2025.
  • Business Quant data shows Common Equity for VIR at $765.3 million in Q4 2025, $796.1 million in Q3 2025, and $947.5 million in Q2 2025.